NCT03235739View on ClinicalTrials.gov

Ancillary Effects of Oral Naloxegol (Movantik)

PHASE4CompletedINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

October 1, 2017

Primary Completion Date

May 31, 2021

Study Completion Date

May 23, 2022

Conditions
Pain, Postoperative
Interventions
DRUG

Naloxegol 25 MG

Oral Naloxegol 25 MG

DRUG

Placebo

matching oral placebo

Trial Locations (1)

44195

The Cleveland Clinic Foundation, Cleveland

All Listed Sponsors
lead

The Cleveland Clinic

OTHER

NCT03235739 - Ancillary Effects of Oral Naloxegol (Movantik) | Biotech Hunter | Biotech Hunter